<DOC>
	<DOCNO>NCT01845584</DOCNO>
	<brief_summary>Patients diagnose anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder confirm base diagnostic criterion . Patients meet inclusion criterion conflict exclusion criterion receive steroid plus therapy （1g/day five consecutive days） . Subsequently , patient provide adequate effect therapy steroid plus therapy receive NPB-01 ( intravenous immunoglobulin ) 400mg/kg/day five consecutive day . Patients evaluated Quantification nerve spinal cord impairment （QOSI） Expanded Disability Status Scale （EDSS）/ Functional Systems （FS） anti-aquaporin 4 antibody et al . As safety endpoint , safety NPB-01 investigate occurrence adverse event one year start study treatment .</brief_summary>
	<brief_title>Phase II Clinical Trial NPB-01 Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect Therapy Steroids Plus Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Patients become positive antiaquaporin 4 antibody become . 2 . Patients develop myelitis . 3 . Patients run beyond great 30 day least last time relapse . 4 . Patients new neurological symptom worsen neurological symptom flare neurological symptom sustain 24 hour least associate fever infection . 5 . Patients acute exacerbation inform consent . 6 . Patients need steroid plus therapy（1g/day five consecutive days） . 7 . Patients start steroid plus therapy within 3 day inform consent . 8 . Patients inadequate effect steroid plus therapy . 9 . Patients great equal twenty year old informed consent . 1 . Patients develop optic neuritis . 2 . Patients treat intravenous immunoglobulin within 14 day inform consent . 3 . Patients malignancy inform consent . 4 . Patients history shock hypersensitivity NPB01 . 5 . Patients IgA deficiency . 6 . Patients impaired liver function . 7 . Patients impaired renal function . 8 . Patients cerebro cardiovascular disorder . 9 . Patients high risk thromboembolism . 10 . Patients hemolytic/hemorrhagic anemia . 11 . Patients decrease cardiac function . 12 . Patients decreased platelet .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>IVIG Neuromyelitis Optica spectrum disorder</keyword>
	<keyword>Patients Neuromyelitis Optica spectrum disorder</keyword>
</DOC>